MILESTONE SCIENTIFIC INC (MLSS) Fundamental Analysis & Valuation
NYSEARCA:MLSS • US59935P2092
Current stock price
0.2464 USD
-0.05 (-15.62%)
At close:
0.29 USD
+0.04 (+17.69%)
After Hours:
This MLSS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MLSS Profitability Analysis
1.1 Basic Checks
- In the past year MLSS has reported negative net income.
- In the past year MLSS has reported a negative cash flow from operations.
- MLSS had negative earnings in each of the past 5 years.
- MLSS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- MLSS's Return On Assets of -86.63% is on the low side compared to the rest of the industry. MLSS is outperformed by 77.72% of its industry peers.
- The Return On Equity of MLSS (-208.80%) is worse than 75.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.63% | ||
| ROE | -208.8% | ||
| ROIC | N/A |
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MLSS has a Gross Margin of 72.80%. This is amongst the best in the industry. MLSS outperforms 82.61% of its industry peers.
- MLSS's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for MLSS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
2. MLSS Health Analysis
2.1 Basic Checks
- MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MLSS has more shares outstanding
- The number of shares outstanding for MLSS has been increased compared to 5 years ago.
- MLSS has a worse debt/assets ratio than last year.
2.2 Solvency
- MLSS has an Altman-Z score of -21.11. This is a bad value and indicates that MLSS is not financially healthy and even has some risk of bankruptcy.
- MLSS has a worse Altman-Z score (-21.11) than 90.76% of its industry peers.
- MLSS has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
- MLSS has a Debt to Equity ratio (0.25) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -21.11 |
ROIC/WACCN/A
WACC10.14%
2.3 Liquidity
- MLSS has a Current Ratio of 2.03. This indicates that MLSS is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of MLSS (2.03) is worse than 63.04% of its industry peers.
- A Quick Ratio of 0.69 indicates that MLSS may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.69, MLSS is doing worse than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.03 | ||
| Quick Ratio | 0.69 |
3. MLSS Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 37.92% over the past year.
- The Revenue for MLSS has decreased by -12.19% in the past year. This is quite bad
- Measured over the past years, MLSS shows a small growth in Revenue. The Revenue has been growing by 0.61% on average per year.
EPS 1Y (TTM)37.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-12.19%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-6.11%
3.2 Future
- MLSS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.70% yearly.
- MLSS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.17% yearly.
EPS Next Y20.67%
EPS Next 2Y14.89%
EPS Next 3Y9.7%
EPS Next 5YN/A
Revenue Next Year-0.48%
Revenue Next 2Y3.44%
Revenue Next 3Y4.17%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. MLSS Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MLSS. In the last year negative earnings were reported.
- Also next year MLSS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.89%
EPS Next 3Y9.7%
5. MLSS Dividend Analysis
5.1 Amount
- MLSS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MLSS Fundamentals: All Metrics, Ratios and Statistics
0.2464
-0.05 (-15.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-27 2026-03-27/bmo
Inst Owners5.75%
Inst Owner Change1.53%
Ins Owners2.94%
Ins Owner Change-1.08%
Market Cap19.37M
Revenue(TTM)8.63M
Net Income(TTM)-6.97M
Analysts82.5
Price Target1.02 (313.96%)
Short Float %0.27%
Short Ratio0.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.4%
Min EPS beat(2)-96.08%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-104.25%
Min EPS beat(4)-194.12%
Max EPS beat(4)-30.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.25%
Min Revenue beat(2)-12.41%
Max Revenue beat(2)-10.09%
Revenue beat(4)0
Avg Revenue beat(4)-13.44%
Min Revenue beat(4)-25.64%
Max Revenue beat(4)-5.64%
Revenue beat(8)0
Avg Revenue beat(8)-18.46%
Revenue beat(12)3
Avg Revenue beat(12)-10.19%
Revenue beat(16)5
Avg Revenue beat(16)-9.84%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.13 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.8 | ||
| P/tB | 6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.12
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.63% | ||
| ROE | -208.8% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.8% | ||
| FCFM | N/A |
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
F-Score3
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 16.55% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.03 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | -21.11 |
F-Score3
WACC10.14%
ROIC/WACCN/A
Cap/Depr(3y)17.16%
Cap/Depr(5y)20.45%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y20.67%
EPS Next 2Y14.89%
EPS Next 3Y9.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.19%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-6.11%
Revenue Next Year-0.48%
Revenue Next 2Y3.44%
Revenue Next 3Y4.17%
Revenue Next 5YN/A
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.04%
OCF growth 3YN/A
OCF growth 5YN/A
MILESTONE SCIENTIFIC INC / MLSS Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MILESTONE SCIENTIFIC INC?
ChartMill assigns a fundamental rating of 2 / 10 to MLSS.
What is the valuation status of MILESTONE SCIENTIFIC INC (MLSS) stock?
ChartMill assigns a valuation rating of 0 / 10 to MILESTONE SCIENTIFIC INC (MLSS). This can be considered as Overvalued.
Can you provide the profitability details for MILESTONE SCIENTIFIC INC?
MILESTONE SCIENTIFIC INC (MLSS) has a profitability rating of 1 / 10.
What is the earnings growth outlook for MILESTONE SCIENTIFIC INC?
The Earnings per Share (EPS) of MILESTONE SCIENTIFIC INC (MLSS) is expected to grow by 20.67% in the next year.